Polatuzumab vedotin-bendamustine-rituximab (PBR) versus tafasitamab-lenalidomide (TafaL) in ASCT-transplant ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Economic evaluation including novel metrics.

Matthias Calamia,Ali McBride,Ivo Abraham

Polatuzumab vedotin-bendamustine-rituximab (PBR) versus tafasitamab-lenalidomide (TafaL) in ASCT-transplant ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Economic evaluation including novel metrics.

2021

Matthias Calamia
Ali McBride
Ivo Abraham

e19535Background: PBR and TafaL are two recently regulatory approved regimens that offer treatment options for R/R DLBCL patients who are ASCT ineligible or choose not to undergo ASCT. PBR is admin...

Keywords:

Bendamustine/rituximab
treatment options
Medicine
Oncology
Diffuse large B-cell lymphoma
transplant ineligible
Lenalidomide
Internal medicine
Polatuzumab vedotin
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations